|本期目录/Table of Contents|

[1]王梦玥,李腾,蒋曙光,等.脂质体共递药系统用于肿瘤联合治疗的新进展[J].生物加工过程,2018,16(05):33-41.[doi:10.3969/j.issn.1672-3678.2018.05.005]
 WANG Mengyue,LI Teng,JIANG Shuguang,et al.Recent advances in liposome-based co-delivery systems for combination cancer therapy[J].Chinese Journal of Bioprocess Engineering,2018,16(05):33-41.[doi:10.3969/j.issn.1672-3678.2018.05.005]
点击复制

脂质体共递药系统用于肿瘤联合治疗的新进展()
分享到:

《生物加工过程》[ISSN:1672-3678/CN:32-1706/Q]

卷:
16
期数:
2018年05期
页码:
33-41
栏目:
出版日期:
2018-09-29

文章信息/Info

Title:
Recent advances in liposome-based co-delivery systems for combination cancer therapy
文章编号:
1672-3678(2018)05-0033-09
作者:
王梦玥李腾蒋曙光莫然
中国药科大学 高端药物制剂与材料研究中心,江苏 南京 210009
Author(s):
WANG MengyueLI TengJIANG ShuguangMO Ran
Center of Advanced Pharmaceuticals and Biomaterials,China Pharmaceutical University,Nanjing 210009,China
关键词:
脂质体 共递药系统 联合治疗 癌症 生物材料
分类号:
R944.1
DOI:
10.3969/j.issn.1672-3678.2018.05.005
文献标志码:
A
摘要:
肿瘤联合治疗是临床癌症治疗的常用手段,指通过应用两种或两种以上的药物发挥协同作用从而提高抗癌效果。脂质体是一种药物载体,近年来被广泛用于多种抗癌药物的共递送。本文中,笔者主要介绍脂质体的发展以及脂质体共载体系用于癌症联合治疗的研究进展。

参考文献/References:

[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
[2] KE X,SHEN L S.Molecular targeted therapy of cancer:the progress and future prospect[J].Front Lab Med,2017,1(2):69-75.
[3] CHAN C W H,TSUI S K W,LAW B M H,et al.The utilization of the immune system in lung cancer treatment:beyond chemotherapy[J].Int J Mol Sci,2016,17(3):286.
[4] MA J L,HENNESSEY D B,NEWELL B P,et al.Radiotherapy-related complications presenting to a urology department:a more common problem than previously thought[J].BJU Int,2018,121(S3):28-32.
[5] XU X,HO W,ZHANG X,et al.Cancer nanomedicine:from targeted delivery to combination therapy[J].Trends Mol Med,2015,21(4):223-232.
[6] SHI J J,KANTOFF P W,WOOSTER R,et al.Cancer nanomedicine:progress,challenges and opportunities[J].Nat Rev Cancer,2017,17(1):20-37.
[7] PATTNI B S,CHUPIN V V,TORCHILIN V P.New developments in liposomal drug delivery[J].Chem Rev,2015,115(19):10938-10966.
[8] KIM Y J,LIU Y,LI S,et al.Co-eradication of breast cancer cells and cancer stem cells by cross-linked multilamellar liposomes enhances tumor treatment[J].Mol Pharm,2015,12(8):2811-2822.
[9] PARK J,WRZESINSKI S H,STERN E,et al.Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy[J].Nat Mater,2012,11(10):895-905.
[10] BANGHAM A D.A correlation between surface charge and coagulant action of phospholipids[J].Nature,1961,192:1197-1198.
[11] BANGHAM A D,REES K R,SHOTLANDER V.Penetration of lipid films by compounds preventing liver necrosis in rats[J].Nature,1962,193:754-756.
[12] BANGHAM A D,STANDISH M M,WATKINS J C.Diffusion of univalent ions across the lamellae of swollen phospholipids[J].J Mol Biol,1965,13(1):238-252.
[13] GREGORIADIS G,RYMAN B E.Lysosomal localization of β-fructofuranosidase-containing liposomes injected into rats[J].Biochem J,1972,129(1):123-133.
[14] ZOU Y,XIA Y,ZHANG J,et al.GE11-directed functional polymersomal doxorubicin as an advanced alternative to clinical liposomal formulation for ovarian cancer treatment[J].Mol Pharm,2018,DOI:10.1021/acs.molpharmaceut.8b00024.
[15] CARACCIOLO G.Clinically approved liposomal nanomedicines:lessons learned from the biomolecular corona[J].Nanoscale,2018,10(9):4167-4172.
[16] JOHNSEN K B,GUDBERGSSON J M,DUROUX M,et al.On the use of liposome controls in studies investigating the clinical potential of extracellular vesicle-based drug delivery systems:a commentary[J].J Control Release,2018,269(10):10-14.
[17] SLINGERLAND M,GUCHELAAR H J,GELDERBLOM H.Liposomal drug formulations in cancer therapy:15 years along the road[J].Drug Discov Today,2012,17(3/4):160-166.
[18] MU L M,JU R J,LIU R,et al.Dual-functional drug liposomes in treatment of resistant cancers[J].Adv Drug Deliv Rev,2017,115(1):46-56.
[19] 左勇亮,肖人钟,王蓉蓉.主动靶向脂质体研究进展[J].中国现代应用药学,2013,30(10):1151-1156.
[20] ZYLBERBERG C,GASKILL K,PASLEY S,et al.Engineering liposomal nanoparticles for targeted gene therapy[J].Gene Ther,2017,24(8):441-452.
[21] YUNG B C,LI J,ZHANG M,et al.Lipid nanoparticles composed of quaternary amine-tertiary amine cationic lipid combination(QTsome)for therapeutic delivery of AntimiR-21 for lung cancer[J].Mol Pharm,2016,13(2):653-662.
[22] FELGNER P L,GADEK T R,HOLM M,et al.Lipofection:a highly efficient,lipid-mediated DNA-transfection procedure[J].Proc Natl Acad Sci USA,1987,84(21):7413-7417.
[23] STRIETH S,EICHHORN M E,WERNER A,et al.Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with cisplatin[J].Clin Cancer Res,2008,14(14):4603-4611.
[24] GALANIS E,BURCH P A,RICHARDSON R L,et al.Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma[J].Cancer,2004,101(11):2557-2566.
[25] SHUKLA S,HALDORAI Y,HWANG S K,et al.Current demands for food-approved liposome nanoparticles in food and safety sector[J].Front Microbiol,2017,8:2398.
[26] BATIST G,GELMON K A,CHI K N,et al.Safety,pharmacokinetics,and efficacy of CPX-1 liposome injection in patientswith advanced solid tumors[J].Clin Cancer Res,2009,15(2):692-700.
[27] FELDMAN E J,LANCET J E,KOLITZ J E,et al.First-in-man study of CPX-351:a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia[J].J Clin Oncol,2011,29(8):979-985.
[28] FELDMAN E J,KOLITZ J E,TRANG J M,et al.Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin,in patients with advanced leukemia[J].Leukemia Res,2012,36(10):1283-1289.
[29] NIKANJAM M,CAPPARELLI E V,LANCET J E,et al.Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351:population pharmacokinetic assessment[J].Cancer Chemother Pharmacol,2018,81(1):171-178.
[30] ZUCKER D,BARENHOLZ Y.Optimization of vincristine-topotecan combination:paving the way for improved chemotherapy regimens by nanoliposomes[J].J Control Release,2010,146(3):326-333.
[31] MACKAY J A,CHEN M N,MCDANIEL J R,et al.Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection[J].Nat Mater,2009,8(12):993-999.
[32] FONG C W.Platinum anti-cancer drugs:free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect[J].Free Radic Biol Med,2016,95:216-229.
[33] RUTTALA H B,RAMASAMY T,GUPTA B,et al.Multiple polysaccharide-drug complex-loaded liposomes:a unique strategy in drug loading and cancer targeting[J].Carbohydr Polym,2017,173(1):57-66.
[34] 范晓慧.紫杉醇阿霉素共载药胶束的制备及体内外评价[D].济南:山东大学,2016.
[35] LIU Y R,FANG J X,KIM Y J,et al.Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity[J].Mol Pharm,2014,11(5):1651-1661.
[36] JIANG T Y,MO R,BELLOTI A,et al.Gel-liposome-mediated co-delivery of anticanacer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy[J].Adv Func Mater,2014,24(16):2295-2304.
[37] CHENG Y,ZHAO P X,WU S P,et al.Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma[J].Int J Pharm,2018,545(1):261-273.
[38] MONTAZERI M,SADEGHIZADEH M,PILEHVAR-SOLTANAHMADI Y,et al.Dendrosomal curcumin nanoformulation modulate apoptosis-related genes and protein expression in hepatocarcinoma cell lines[J].Int J Pharm,2016,509(1):244-254.
[39] 杨建苗,李天傲,许东航.多柔比星-五味子乙素共载脂质体克服多药耐药的机制研究[J].中国现代应用药学,2017,34(12):1679-1682.
[40] 于跃,王军飞,王长云,等.抗多药耐药紫杉烷类抗肿瘤药物研究进展[J].中国现代应用药学,2012,29(1):16-23.
[41] KONG F,ZHANG X,ZHANG H,et al.Inhibition of multidrug resistance of cancer cells by co-delivery of dna nanostructures and drugs using porous silicon nanoparticles@giant liposomes[J].Adv Funct Mater,2015,25(22):3330-3340.
[42] CHEN Y,CHENG Y,ZHAO P X,et al.Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance[J].Int J Pharm,2018,542(1):266-279.
[43] ANREDDY N,GUPTA P,KATHAWALA J R,et al.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance[J].Molecules,2014,19(9):13848-13877.
[44] DENG Z J,MORTON S W,BEN-AKIVA E,et al.Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment[J].ACS Nano,2013,7(11):9571-9584.
[45] QU M H,ZENG R F,FANG S,et al.Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer[J].Int J Pharm,2014,474(1/2):112-122.
[46] REDDY T L,GARIKAPATI K R,REDDY S G,et al.Simultaneous delivery of paclitaxel and Bcl-2 siRNA via pH-sensitive liposomal nanocarrier for the synergistic treatment of melanoma[J].Sci Rep,2016,6:35223.
[47] DANHIER F,FERON O,PREAT V.To exploit the tumor microenvironment:passive and active tumor targeting of nanocarriers for anti-cancer drug delivery[J].J Control Release,2010,148(2):135-146.
[48] KHAWAR I A,KIM J H,KUH H J.Improving drug delivery to solid tumors:priming the tumor microenvironment[J].J Control Release,2015,201(10):78-89.
[49] SUN Y.Tumor microenvironment and cancer therapy resistance[J].Cancer Lett,2016,380(1):205-215.
[50] MO R,GU Z.Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery[J].Mater Today,2016,19(5):274-283.
[51] JI T J,LI S P,ZHANG Y L,et al.An MMP-2 responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer[J].ACS Appl Mater Interfaces,2016,8(5):3438-3445.
[52] LV Y Q,XU C R,ZHAO X M,et al.Nanoplatform assembled from a cd44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells[J].ACS Nano,2018,12(2):1519-1536.
[53] KIM J M,CHEN D S.Immune escape to PD-L1/PD-1 blockade:seven steps to success(or failure)[J].Ann Oncol,2016,27(8):1492-1504.
[54] BYUN D J,WOLCHOK J D,ROSENBERG L M,et al.Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies[J].Nat Rev Endocrinol,2017,13(4):195-207.
[55] YOON H Y,SELVAN S T,YANG Y,et al.Engineering nanoparticle strategies for effective cancer immunotherapy[J/OL].[2018-04-21].Biomaterials,2018,https://doi.org/10.1016/j.biomaterials.2018.03.036.
[56] TENG F F,MENG X J,KONG L,et al.Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy:a systematic review[J].Cancer Lett,2018,414:166-173.
[57] SHARMA P,HU-LIESKOVAN S,WARGO J A,et al.Primary,adaptive,and acquired resistance to cancer immunotherapy[J].Cell,2017,168(4):707-723.
[58] LIANG R J,XIE J,LI J,et al.Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response[J].Biomaterials,2017,149:41-50.

相似文献/References:

[1]任文霞,李建科.逆相蒸发法制备茶多酚脂质体及质量评价[J].生物加工过程,2009,7(02):68.
 REN Wen-xia,LI Jian-ke.Preparation and quality evaluation of tea polyphenol liposomes by reverse-phase evaporation[J].Chinese Journal of Bioprocess Engineering,2009,7(05):68.

备注/Memo

备注/Memo:
收稿日期:2018-04-25修回日期:2018-07-11
基金项目:国家自然科学基金(81673381); 江苏省自然科学基金杰出青年基金(BK20150029)
作者简介:王梦玥(1993—),女,辽宁本溪人,硕士研究生,研究方向:药用功能材料与靶向递药系统; 蒋曙光(联系人),副教授,E-mail:cpujsg@163.com; 莫然(联系人),教授,E-mail:rmo@cpu.edu.cn
引文格式:王梦玥,李腾,蒋曙光,等.脂质体共递药系统用于肿瘤联合治疗的新进展[J].生物加工过程,2018,16(5):33-41.
WANG Mengyue,LI Teng,JIANG Shuguang,et al.Recent advances in liposome-based co-delivery systems for combination cancer therapy[J].Chin J Bioprocess Eng,2018,16(5):33-41..
更新日期/Last Update: 2018-09-30